

GLAXOSMITHKLINE PLC  
Form 6-K/A  
July 27, 2010

**FORM 6-K/A**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

This announcement replaces the original announcement released on 1 July 2010.

The Company was notified on the 27 July 2010 of a correction to the number of shares provisionally allocated to the Company's Non-Executive Directors' Mr Lawrence Culp and Sir Deryck Maughan pursuant to the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2010 to 30 June 2010.

Save as disclosed above and the revised details shown below, all other details remain unchanged.

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 30 June 2010, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £11.37 per Ordinary share and \$34.05 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2010 to 30 June 2010:

**Non Executive Director    Ordinary Shares    American Depository Shares (ADSs)**

Sir Christopher Gent	2,968.34	
Prof. Sir Roy Anderson	577.18	
Dr Stephanie Burns		809.11
<R> Mr Lawrence Culp		1,258.61 </R>
Sir Crispin Davis	2,088.83	
<R> Sir Deryck Maughan		1,258.61 </R>
Mr James Murdoch	1,649.08	
Dr Daniel Podolsky		1,483.36
Mr Tom de Swaan	852.02	
Sir Robert Wilson	577.18	

The Company and the Non-Executive Directors were informed of these allocations on 1 July 2010.

This notification relates to transactions notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary  
1 July 2010

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 27, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc